Bullish indicating open at $55-$60, IPO prices at $37
IRVING, Texas - Caris Life Sciences , Inc. (NASDAQ:CAI) shares jumped 7.8% after the AI TechBio company reported strong second-quarter results and provided full-year revenue guidance that significantly exceeded analyst expectations.
The company reported second-quarter revenue of $181.4 million, representing an 81.3% increase compared to the same period last year. While the company posted a net loss of $71.8 million, or -$7.97 per share, it achieved positive adjusted EBITDA of $16.7 million and positive free cash flow of $5.9 million for the quarter. The net loss included $37.1 million in one-time expenses associated with the conversion of preferred stock, warrants, and convertible notes from its initial public offering.
Caris Life Sciences provided full-year 2025 revenue guidance of $675-685 million, substantially above the analyst consensus of $588 million. This outlook represents 64-66% growth compared to full year 2024.
"Our second quarter results show the strength of our comprehensive approach and we look forward to continuing to build on this momentum into the second half of 2025," said David D. Halbert, Founder, Chairman and CEO of Caris Life Sciences.
The company’s molecular profiling services revenue grew 85.9% YoY to $162.9 million, driven by a 22% increase in clinical case volume and significant improvements in average selling prices. Gross margin expanded dramatically to 62.7%, a 25.2 percentage point improvement from 37.5% in the year-ago quarter.
Caris completed 50,032 clinical therapy selection cases during the quarter, up 22% from the same period last year. The company also reported positive operating cash flow of $7.3 million, a significant improvement from negative $62.9 million in the prior-year quarter.
The company recently completed its initial public offering in June 2025, raising $519.5 million in net proceeds, strengthening its balance sheet with $724.9 million in cash and marketable securities as of June 30.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.